A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency
NACompletedINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
June 7, 2018
Primary Completion Date
March 30, 2019
Study Completion Date
March 31, 2019
Conditions
Angina
Interventions
DRUG
Ranolazine
Oral, b.i.d
DRUG
Placebos
Oral, b.i.d
Trial Locations (1)
10048
National Taiwan University Hospital, Taipei
All Listed Sponsors
lead
TSH Biopharm Corporation Limited
INDUSTRY
NCT03401502 - A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency | Biotech Hunter | Biotech Hunter